Multifaceted interactions between lentiviral Vif and host molecules for viral infectivity enhancement

慢病毒 Vif 与宿主分子之间的多方面相互作用增强病毒感染力

• 批准号: 10774368
• 负责人: Yong Xiong
• 金额: $ 7.39万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-06-15 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10774368
• 关键词: 3-Dimensional; Binding; Biochemical; Biophysics; CD4 Positive T Lymphocytes; Capsid Proteins; Cell Cycle Arrest; Classification; Communities; Comparative Study; Complex; Cryoelectron Microscopy; Cyclophilin A; Cytidine Deaminase; Deamination; Degradation Pathway; Evolution; Fluorescence; Goals; HIV; HIV-1; Host Defense Mechanism; Immune; Immune system; In Vitro; Infection; Integration Host Factors; Invaded; Knowledge; Mammals; Mediating; Methods; Molecular; Mutagenesis; PPP2R5A gene; Pathway interactions; Peptidylprolyl Isomerase; Primate Lentiviruses; Protein Family; Protein Isoforms; Protein phosphatase; Proteins; Research; Research Design; Research Project Grants; Resolution; Reverse Transcription; Sheep; Spectrum Analysis; Structure; System; Techniques; Therapeutic; Transcript; Ubiquitin; Validation; Viral; Viral Physiology; Viral Proteins; Virion; Virus Diseases; Virus Inhibitors; Virus Replication; Visna-maedi virus; Work; X-Ray Crystallography; cellular targeting; cofactor; combat; design; experimental study; factor A; in vivo; inhibitor; insight; multicatalytic endopeptidase complex; novel therapeutics; pathogen; reconstruction; recruit; structural biology; tool; transcription factor; ubiquitin-protein ligase

PROJECT DESCRIPTION The APOBEC3 (A3) family of proteins are cellular cytidine deaminases that suppress human immunodeficiency virus type 1 (HIV-1) infection by hypermutation of viral reverse transcripts and physically blocking reverse transcription. To evade this host defense mechanism, HIV-1 expresses the virion infectivity factor (Vif), which hijacks a cellular E3 ubiquitin ligase complex and targets A3 proteins (A3F/G/H/D) for proteasome-mediated degradation. Besides degrading A3s, HIV-1 Vif also causes G2 cell cycle arrest by targeting multiple protein phosphatase 2A (PP2A) regulators (PPP2R5 proteins) for degradation. Adding to the complexity of Vif-host protein interactions, HIV-1 Vif utilizes the transcription factor CBFβ as a non-canonical cofactor, while maedi-visna virus (MVV) Vif co-opts the prolyl isomerase cyclophilin A (CypA) instead. Our goal is to establish the biochemical and structural principles for the multifaceted activities of lentiviral Vif molecules that recruit cellular factors to degrade host proteins via ubiquitin-proteasome pathways. To achieve our goal, we will use a combination of biochemical, biophysical, structural biology, and cellular functional techniques. To establish the mechanisms by which A3 proteins are targeted by the HIV-1 Vif (Aim1), we will determine high- resolution structures of the A3-Vif-E3 interaction complexes, validate these structures by structure-guided mutagenesis experiments in vitro and in vivo, and interrogate the molecular determinants of Vif/A3/E3 ligase assembly and activation. In addition, we will also study the degradation-independent mode of Vif inhibition of A3 deamination and antiviral activities. To better understand CypA-mediated formation of MVV Vif-E3 ubiquitin ligase (Aim2), we will assemble MVV Vif/CypA/E3 ligase complexes with or without A3 substrates, determine their high-resolution structures, and perform biochemical and functional validations of our structural observations. The influences of capsid proteins on the assembly and activation of MVV Vif-E3 ligase will also be investigated. To delineate the mechanisms of PPP2R5/PP2A recruitment by lentiviral Vif-E3 ubiquitin ligases (Aim3), we will investigate the effects of PPP2R5 proteins on the assemblies of the CBFβ-mediated HIV-1 Vif and CypA-mediated MVV Vif-E3 ligases, obtain high-resolution structures, and perform structure- guided validations. Our comprehensive research design provides a robust approach that will generate unprecedented insights into the diverse functions of lentiviral Vif molecules.

项目描述 APOBEC 3（A3）蛋白家族是细胞胞苷脱氨酶，其抑制人类免疫应答。 免疫缺陷病毒1型（HIV-1）感染通过病毒逆转录和物理 阻断逆转录。为了逃避这种宿主防御机制，HIV-1表达了病毒粒子的感染性， 因子（Vif），其劫持细胞E3泛素连接酶复合物并靶向A3蛋白（A3 F/G/H/D）， 蛋白酶体介导的降解。除了降解A3，HIV-1 Vif还通过以下方式引起G2细胞周期阻滞： 靶向多种蛋白磷酸酶2A（PP 2A）调节剂（PPP 2 R5蛋白）进行降解。增加了 由于Vif与宿主蛋白质相互作用的复杂性，HIV-1 Vif利用转录因子CBFβ作为非经典转录因子。 辅因子，而梅迪-维斯纳病毒（MVV）Vif替代脯氨酰异构酶亲环素A（CypA）。我们的目标 是建立慢病毒Vif分子多方面活动的生物化学和结构原理 通过泛素-蛋白酶体途径募集细胞因子降解宿主蛋白质。为了实现我们的目标， 我们将结合使用生物化学、生物物理学、结构生物学和细胞功能技术。到 建立A3蛋白被HIV-1 Vif（Aim 1）靶向的机制，我们将确定高水平的 A3-Vif-E3相互作用复合物的解析结构，通过结构引导的 体外和体内诱变实验，并询问Vif/A3/E3连接酶的分子决定簇 组装和激活。此外，我们还将研究Vif抑制的非降解依赖模式， A3脱氨基和抗病毒活性。为了更好地理解CypA介导的MVV Vif-E3泛素形成 连接酶（Aim 2），我们将组装MVV Vif/CypA/E3连接酶复合物，有或没有A3底物，确定 他们的高分辨率结构，并执行生化和功能验证我们的结构 意见。本文还研究了衣壳蛋白对MVV Vif-E3连接酶组装和活化的影响。 追究描述慢病毒Vif-E3泛素募集PPP 2 R5/PP 2A的机制 连接酶（Aim 3），我们将研究PPP 2 R5蛋白对CBFβ介导的 HIV-1 Vif和CypA介导的MVV Vif-E3连接酶，获得高分辨率结构，并进行结构- 引导验证。我们全面的研究设计提供了一个强大的方法，将产生 这是对慢病毒Vif分子的多种功能的前所未有的了解。

项目成果

FBXO32, encoding a member of the SCF complex, is mutated in dilated cardiomyopathy.

• DOI: 10.1186/s13059-015-0861-4
• 发表时间: 2016-01-11
• 期刊: Genome biology
• 影响因子: 12.3
• 作者: Al-Yacoub N;Shaheen R;Awad SM;Kunhi M;Dzimiri N;Nguyen HC;Xiong Y;Al-Buraiki J;Al-Habeeb W;Alkuraya FS;Poizat C
• 通讯作者: Poizat C

Exploring ABOBEC3A and APOBEC3B substrate specificity and their role in HPV positive head and neck cancer.

• DOI: 10.1016/j.isci.2022.105077
• 发表时间: 2022-10-21
• 期刊: ISCIENCE
• 影响因子: 5.8
• 作者: Papini, Christina;Wang, Zechen;Kudalkar, Shalley N.;Schrank, Travis Parke;Tang, Su;Sasaki, Tomoaki;Wu, Cory;Tejada, Brandon;Ziegler, Samantha J.;Xiong, Yong;Issaeva, Natalia;Yarbrough, Wendell G.;Anderson, Karen S.
• 通讯作者: Anderson, Karen S.